Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026

Rigel reported pooled ARROW and TAPISTRY data showing a 53% overall response rate and median response duration of 12.2 months among 49 patients with RET fusion-positive solid tumors, excluding NSCLC and thyroid cancer; previously treated pancreatic cancer patients had an 88% response rate (7/8). Separate analyses reported an 81.3% response rate in 16 evaluable RET fusion-positive thyroid cancer patients and a 75% first-line response rate in RET fusion-positive NSCLC patients treated with pralsetinib, versus 26% for patients previously given standard first-line therapies. The results will be presented at ESMO Congress 2026; the release also notes important safety risks, including serious infections and pneumonitis.

Analysis

The market mechanism is better evidence for GAVRETO’s existing RET niches and a possible future tumor-agnostic label—not an immediate reset to Rigel’s revenue base. The broad-tumor signal is hypothesis-generating: 49 patients across tumor types and only eight pancreatic cases make the headline response rates vulnerable to selection and small-sample effects. It does not establish a new reimbursable market or displace the need for regulatory-grade evidence. In NSCLC, the first-line comparison is against patients treated before ARROW enrollment, not a randomized contemporaneous control; raw response-rate differences should not be treated as proof of superiority.

The October 25 ESMO presentation is the near-term catalyst. Full denominators, duration-of-response follow-up, discontinuations, and subgroup safety will matter more than the topline ORRs. Over 1–3 months, physician uptake and testing rates—not conference attention—would be the relevant commercial confirmation. Over 6–18 months, tumor-agnostic development and thyroid confirmatory requirements matter, but the release provides no new regulatory milestone. Lilly’s Retevmo is the key competitive benchmark: durable efficacy, tolerability, and practical use will determine share, not activity in isolation. Serious infection and pneumonitis risks could constrain persistence. Contrarian view: enthusiasm may overprice a broader indication before evidence or approval; alternatively, the niche’s value may be underappreciated if fuller data show durable benefit in hard-to-treat tumors. No supplied valuation, sales, or price data supports sizing a directional position.

Key Decisions for Investors

• No immediate trade on the press release alone; avoid chasing a gap higher in RIGL before reviewing the October 25 presentation.
• Event watch: reassess after ESMO for patient-level denominators, duration-of-response maturity, treatment discontinuations, and grade 3+ adverse events; compare NSCLC evidence with Retevmo rather than historical controls alone.
• Treat tumor-agnostic expansion as an option, not base-case earnings: require a credible regulatory path and evidence beyond small, selected subgroups before underwriting incremental sales.
• Falsification signals: materially shorter response durability or more treatment-limiting toxicity in full data, no follow-on regulatory/development plan, or management commentary that does not translate the findings into measurable commercial or trial milestones.